BIPSX — Biotechnology
Data updated: 2026-06-22
BIPSX — Biotechnology data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. Leveraged · $182.58M AUM · 2.52% expense ratio · 86.2% 1-yr return. From SEC regulatory filings.
BIPSX Fund Overview
BIPSX — Biotechnology is a US mutual fund managed by ProFunds, categorised as Leveraged. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: ProFunds
- Category: Leveraged
- Assets under management: $182.58M
- 1-year return: 86.2%
- Ticker: BIPSX
- SEC CIK: 0001039803
- SEC series ID: S000003107
- Share class ID: C000008430
BIPSX Holdings
Top 10 holdings of Biotechnology by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Agpxx | 2.05% |
| Apellis Pharmaceuticals, Inc. | 1.35% |
| Revolution Medicines, Inc. | 1.19% |
| Travere Therapeutics, Inc. | 1.17% |
| Arrowhead Pharmaceuticals, Inc. | 1.04% |
| Twist Bioscience Corp. | 1.03% |
| Summit Therapeutics, Inc. | 1.01% |
| Alkermes PLC | 1.00% |
| Tg Therapeutics, Inc. | 0.99% |
| Madrigal Pharmaceuticals, Inc. | 0.99% |
BIPSX Portfolio Allocation
Asset-class allocation of Biotechnology by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 72.3% |
| Cash & Equivalents | 31.9% |
BIPSX Performance
Total returns for BIPSX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 9.0% |
| 1 year | 86.2% |
| 3 years (annualised) | 18.7% |
| 5 years (annualised) | 9.2% |
BIPSX Risk Information
Risk metrics for BIPSX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 26.7%
BIPSX Costs and Fees
BIPSX costs about $252 per $10,000 invested per year in fund expenses.
- Net expense ratio: 2.52%
- Gross expense ratio: 2.52%
- Portfolio turnover: 52%
- Brokerage commissions: 1.35 bps of average net assets (SEC N-CEN)
BIPSX Cashflows
Over the 12 months to 2026-04, Biotechnology had net inflows of $57.88M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | $172.55K |
| 2026-03 | −$2.87M |
| 2026-02 | −$2.71M |
| 2026-01 | −$6.57M |
| 2025-12 | $73.34M |
| 2025-11 | $6.07M |
BIPSX Debt Constituents
No individual debt constituents are reported in Biotechnology's latest SEC N-PORT filing.
BIPSX Prospectus and SEC Filings
Official Biotechnology filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other Leveraged funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.